


















Investors & Media | BELLUS Health













        Skip to main navigation
      



 

Contact UsENSearch:













Toggle Navigation






Search:












EN




Main navigation
About UsOur CompanyManagement TeamBoard of DirectorsClinical Advisory BoardsContact UsPipelineBLU-5937Chronic CoughChronic PruritusClinical TrialsScienceP2X3 InhibitionScientific PublicationsInvestors & MediaInvestors HomePress ReleasesEvents & PresentationsFinancial Reports & OtherSEC FilingsOther FilingsStock InformationStock Quote & ChartAnalyst CoverageCorporate GovernanceDocuments & ChartersManagementBoard of DirectorsClinical Advisory BoardsCommittee CompositionInvestor ResourcesInvestor ContactFAQsEmail Alerts





















Investors & Media

                                                            Investors Home
                                                    

















              Investors & Media
          







Corporate Profile

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders.










NASDAQ
TSX









 
May 18, 2021


 / 






  Data Provided by Refinitiv. Minimum 15 minutes delayed.


















 
May 18, 2021


 / 


May 18, 2021


 / 






  Data Provided by Refinitiv. Minimum 15 minutes delayed.





























Investors & Media
Investors HomePress ReleasesEvents & PresentationsFinancial Reports & OtherStock InformationCorporate GovernanceInvestor Resources













Recent News





5/12/21



BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

LAVAL, Quebec --(BUSINESS WIRE)--May 12, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders,...
Read More




5/10/21



BELLUS Health Reports First Quarter 2021 Financial Results and Business Highlights

- Phase 2b SOOTHE and Phase 2a BLUEPRINT clinical trials on track, with topline results expected Q4 2021 - - Ended quarter with US$81.9 million in cash, cash equivalents and short-term investments; current cash position expected to be sufficient to fund operating plan until end of 2022 - LAVAL,...
Read More




5/10/21



BELLUS Health to Present at the American Thoracic Society 2021 International Conference

LAVAL, Quebec --(BUSINESS WIRE)--May 10, 2021-- BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitization-related disorders,...
Read More





z - Home >> Recent News > Button
More News












Upcoming Events





  5/19/21




2021 RBC Capital Markets Global Healthcare Conference

Learn More





z - Home >> Upcoming Events > Button
More Events













Corporate Presentation


View




















                            BELLUS Health Inc.
                            
                            275 Armand-Frappier Blvd.
                            
                            Laval, Quebec
                            
                            Canada H7V 4A7
                        







                            Tel.: (450) 680-4500

                            Fax: (450) 680-4501
                            webinfo@bellushealth.com










Footer Nav
Privacy PolicyLegal DisclaimerSite Map

©  BELLUS Health. All Rights Reserved.
















